The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Thursday, September 23, 2021
Bristol Myers Squibb announced that the FDA has accepted for priority review the Biologics License Application (BLA) for the LAG-3-blocking antibody ...
read more
Thursday, September 23, 2021
AbbVie announced that it has submitted an application to the FDA seeking approval for risankizumab-rzaa (600 mg intravenous (IV) induction and 360 mg ...
read more
Thursday, September 23, 2021
Alvotech, a multinational biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets, ...
read more
Thursday, September 23, 2021
Eli Lilly and Company announced a Joint Procurement Agreement with the European Commission (EC) to supply up to 220,000 doses of bamlanivimab and ...
read more
Thursday, September 23, 2021
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-...
read more
Thursday, September 23, 2021
Mayne Pharma is pleased to announce that the FDA has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in adolescents. LEXETTE, a super ...
read more
Thursday, September 23, 2021
Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the generic version of Pfizer...
read more
Thursday, September 23, 2021
AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialization of the proprietary self-...
read more
Thursday, September 23, 2021
The FDA approved ruxolitinib (Jakafi, Incyte Corp.) for chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic ...
read more
Wednesday, September 29, 2021
Merck announced that the Phase 3 KEYNOTE-394 trial investigating KEYTRUDA in Asian patients with advanced hepatocellular carcinoma (HCC) previously ...
read more
Wednesday, September 29, 2021
Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Applications (sBLA) for both Opdivo® (nivolumab) in ...
read more
Thursday, September 30, 2021
Takeda and JCR Pharmaceuticals announced a geographically-focused exclusive collaboration and license agreement to commercialize JR-141 (INN: ...
read more
Thursday, September 30, 2021
Sunovion Pharmaceuticals, its parent company Sumitomo Dainippon Pharma Co and Otsuka Pharmaceutical Co announced today that the companies have entered...
read more
Thursday, September 30, 2021
REGEN-COV significantly reduced viral load in patients hospitalized with COVID-19 who entered the trial without having mounted their own antibody ...
read more
Thursday, September 30, 2021
Eisai and Biogen announced that Eisai has initiated a rolling submission to the FDA of a Biologics License Application (BLA) for lecanemab (BAN2401), ...
read more